search
Back to results

Norspan Transdermal Patches Study in Osteoarthritis Patients

Primary Purpose

Osteoarthritis Disorders

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
buprenorphine
Sponsored by
Mundipharma (China) Pharmaceutical Co. Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis Disorders focused on measuring osteoarthritis disorders

Eligibility Criteria

20 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients volunteering for participation in the study.
  • Male and female patients with diagnosis of osteoarthritis, age from 20 to 60 years.
  • Body weight ≥ 50kg , and BMI range ≧ 18.5, ﹤ 30.
  • Having the results within the following ranges and having been judged as eligible for the study participation by the investigator:Systolic blood pressure (supine), 90-140 mm Hg,Diastolic blood pressure (supine), 60-90 mm Hg, Armpit body temperature, 35.0-37.5 degree Celsius.
  • Agreed not to use any medication (except vitamins or mineral supplements) during the course of the study.
  • Have not smoked or chewed tobacco for at least 45 days prior to dosing with study drugs, and agree not to use tobacco products during the study.
  • Females of childbearing potential must have a negative serum pregnancy test during screening visit and at check-in.

Exclusion Criteria:

  • Subjects who have been taking opioid analgesic formulations excess 7 days within 3 months of Visit 1.
  • Subjects who have been taking CYP3A4 inhibitor or inducer within the last 1 month prior to the screening visit.
  • Subjects who have been taking any medication including OTC (except vitamin and/or mineral supplements) within 7 days prior to the first dose of the trial product.
  • Patients who have a current chronic disease(s), or who have a past history and high possibilities to relapse, in addition to their musculo-skeletal pain, requiring frequent analgesic therapy.
  • Subjects with clinically unstable respiratory disease, dysfunction of the biliary tract, thyroid disease, adrenal cortical insufficiency, prostatic hypertrophy requiring intervention or renal artery stenosis.
  • Subject who have a past history of malignant neoplasm.
  • Subjects with clinically unstable, active or symptomatic heart disease.
  • Subjects who have psychiatric disorder, uncontrolled seizures or convulsive disorder and so on.
  • Subjects who have any medical or surgical conditions that might interfere with transdermal absorption, distribution, metabolism, or excretion of drugs.
  • History of frequent nausea or emesis regardless of etiology.
  • Subjects who have a current or past history of substance or alcohol abuse, or subjects who give a positive result in drug abuse test during the Screening Period.
  • Subjects scheduled for therapies within the study period which might effect study assessment.
  • Subjects with values > 2 times the upper limit of normal for AST or ALT or total bilirubin during the Screening Period or who have severe impaired liver function.
  • Subjects with serum creatinine > 2 mg/dL during the Screening Period or who have severe impaired renal function.
  • Subjects with serum potassium < 3.5 mEq/L during the Screening Period.
  • Subjects with positive result of anti-human immunodeficiency virus antibodies, hepatitis B surface antigen, hepatitis C virus antibody or qualitative syphilis tests.
  • Donated 400 mL or more of blood or blood products within 3 months prior to the start of the study, or donated 200 mL or more of blood or blood products within 1 month prior to the start of the study.
  • Subjects who have a history of supersensitivity to study drug.
  • Subjects who participated in a clinical research study within 1 month of study entry.
  • Subjects who participated previously in a BTDS study.

Sites / Locations

  • Investigational Site: Peking Union Medical Hospital(PUMC)

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

buprenorphine transdermal system

Arm Description

buprenorphine transdermal system

Outcomes

Primary Outcome Measures

Area Under Curve (AUC)

Secondary Outcome Measures

Full Information

First Posted
November 17, 2011
Last Updated
July 7, 2015
Sponsor
Mundipharma (China) Pharmaceutical Co. Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT01643759
Brief Title
Norspan Transdermal Patches Study in Osteoarthritis Patients
Official Title
A Single Dose PK Study of BTDS 5, 10, and 20 in Chinese Osteoarthritis Patients
Study Type
Interventional

2. Study Status

Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
July 2009 (undefined)
Primary Completion Date
March 2010 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mundipharma (China) Pharmaceutical Co. Ltd

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a single center, open label, randomized, parallel group single dose pharmacokinetic (PK) study.
Detailed Description
After up to 7-day screening period, Eligible Patients will be randomized to 1 of 3 treatment groups, and begin treatment with BTDS 5mg, 10mg,20mg for 7 days.Venous blood will be collected at 0, 6, 12, 24, 36, 48, 60, 72, 96,120, 144,168,169,170,171,172,174,180,192,216, 240 h postdose respectively.Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t, AUC0-inf, Cmax, Tmax, t½.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis Disorders
Keywords
osteoarthritis disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
buprenorphine transdermal system
Arm Type
Experimental
Arm Description
buprenorphine transdermal system
Intervention Type
Drug
Intervention Name(s)
buprenorphine
Other Intervention Name(s)
Norspan
Intervention Description
The subjects will be randomized to receive either a single dose of BTDS 5, or BTDS 10, or BTDS 20 for 7 days. Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t:pg•hr/ml-Area under the plasma concentration-time curve frame: predose,6,12,24,36,48,60,72,96,120,144,168,169,170,171,172,174,180,192,216,240 hours post-dose.AUC0-inf:pg•hr/ml-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: pg/ml-Maximum observed plasma buprenorphine concentration. Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of buprenorphine elimination.
Primary Outcome Measure Information:
Title
Area Under Curve (AUC)
Time Frame
Pre-dose, 6hr, 12hr, 24hr, 36hr, 48hr, 60hr, 72hr, 96hr, 120hr, 144hr,168hr, 169hr, 170hr, 171hr, 172hr, 174hr, 180hr, 192hr, 216hr, 240hr post dose.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients volunteering for participation in the study. Male and female patients with diagnosis of osteoarthritis, age from 20 to 60 years. Body weight ≥ 50kg , and BMI range ≧ 18.5, ﹤ 30. Having the results within the following ranges and having been judged as eligible for the study participation by the investigator:Systolic blood pressure (supine), 90-140 mm Hg,Diastolic blood pressure (supine), 60-90 mm Hg, Armpit body temperature, 35.0-37.5 degree Celsius. Agreed not to use any medication (except vitamins or mineral supplements) during the course of the study. Have not smoked or chewed tobacco for at least 45 days prior to dosing with study drugs, and agree not to use tobacco products during the study. Females of childbearing potential must have a negative serum pregnancy test during screening visit and at check-in. Exclusion Criteria: Subjects who have been taking opioid analgesic formulations excess 7 days within 3 months of Visit 1. Subjects who have been taking CYP3A4 inhibitor or inducer within the last 1 month prior to the screening visit. Subjects who have been taking any medication including OTC (except vitamin and/or mineral supplements) within 7 days prior to the first dose of the trial product. Patients who have a current chronic disease(s), or who have a past history and high possibilities to relapse, in addition to their musculo-skeletal pain, requiring frequent analgesic therapy. Subjects with clinically unstable respiratory disease, dysfunction of the biliary tract, thyroid disease, adrenal cortical insufficiency, prostatic hypertrophy requiring intervention or renal artery stenosis. Subject who have a past history of malignant neoplasm. Subjects with clinically unstable, active or symptomatic heart disease. Subjects who have psychiatric disorder, uncontrolled seizures or convulsive disorder and so on. Subjects who have any medical or surgical conditions that might interfere with transdermal absorption, distribution, metabolism, or excretion of drugs. History of frequent nausea or emesis regardless of etiology. Subjects who have a current or past history of substance or alcohol abuse, or subjects who give a positive result in drug abuse test during the Screening Period. Subjects scheduled for therapies within the study period which might effect study assessment. Subjects with values > 2 times the upper limit of normal for AST or ALT or total bilirubin during the Screening Period or who have severe impaired liver function. Subjects with serum creatinine > 2 mg/dL during the Screening Period or who have severe impaired renal function. Subjects with serum potassium < 3.5 mEq/L during the Screening Period. Subjects with positive result of anti-human immunodeficiency virus antibodies, hepatitis B surface antigen, hepatitis C virus antibody or qualitative syphilis tests. Donated 400 mL or more of blood or blood products within 3 months prior to the start of the study, or donated 200 mL or more of blood or blood products within 1 month prior to the start of the study. Subjects who have a history of supersensitivity to study drug. Subjects who participated in a clinical research study within 1 month of study entry. Subjects who participated previously in a BTDS study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mundipharma China Ltd.
Organizational Affiliation
Mundipharma China Ltd.
Official's Role
Study Chair
Facility Information:
Facility Name
Investigational Site: Peking Union Medical Hospital(PUMC)
City
Beijing
Country
China

12. IPD Sharing Statement

Learn more about this trial

Norspan Transdermal Patches Study in Osteoarthritis Patients

We'll reach out to this number within 24 hrs